Naltrexone/Bupropion
by Orexigen Therapeutics
Effective oral appetite control for patients who prefer tablets over injections
6.4%
Average placebo-adjusted weight loss
COR-I trial, Lancet 2010
55%
Patients achieved ≥5% weight loss
COR-I trial, Lancet 2010
28%
Patients achieved ≥10% weight loss
COR-I trial, Lancet 2010
56 weeks
Primary endpoint duration
COR-I trial, Lancet 2010
Mysimba combines two mechanisms: bupropion stimulates POMC (pro-opiomelanocortin) neurons in the hypothalamus to reduce appetite, while naltrexone blocks opioid receptors that would normally suppress POMC activity. Together, they create a sustained reduction in hunger and food cravings, particularly for high-reward foods.
Always follow your prescribing physician's specific instructions. The schedule below is a general guide.
Initiation — one 8mg/90mg tablet each morning
Second dose added in the evening
Third daily tablet added to morning dose
Full maintenance dose — 32mg/360mg daily total
Seek immediate medical attention if you experience any serious adverse effects.
Starting from
$115.00
$1.03/tablet
Reviewed by a licensed US physician
Average 21% body weight loss — the gold standard in medically supervised weight loss
Up to 22.5% body weight loss — the most effective weight loss medication in clinical history
The affordable liraglutide option — same proven GLP-1 mechanism as Saxenda at a lower cost
A licensed US physician will review your consultation, answer all your questions, and prescribe if you're eligible — all from the comfort of home.
No commitment · Reviewed within 24 hours · HIPAA-compliant